Choroidal neovascularization secondary to tuberculosis: Presentation and management

• Main Authors: Esther Lee Kim, Damien C. Rodger, Narsing A. Rao
• Format: Article
• Language: English
• Published: Elsevier 2017-04-01
• Series: American Journal of Ophthalmology Case Reports
• Subjects: Choroidal neovascularization; Tuberculosis; Tuberculous chorioretinitis; Aflibercept
• Online Access: http://www.sciencedirect.com/science/article/pii/S2451993616301815

Purpose: While there are many known etiologies of choroidal neovascularization (CNV), tuberculosis is not a well-known causative agent. In this case series, we highlight CNV occurring secondary to tuberculous chorioretinitis, its presentation, and its management. Observations: We retrospectively reviewed the charts and imaging of four patients who presented with presumed tuberculous chorioretinitis and CNV. Three of these patients had signs of intraocular inflammation and were also found to have active macular CNV. The one remaining patient had chorioretinal scars from prior posterior uveitis and previously treated macular CNV membranes. The three patients with active disease were started on anti-tuberculosis medications and oral corticosteroids, and they also received intravitreal anti-vascular endothelial growth factor (VEGF) injections as needed for the CNV. There was a significant improvement in the clinical course of all three patients with active disease—the intraocular inflammation subsided, and CNV recurrences were mitigated. Upon completion of systemic treatment, all patients have remained quiescent. Conclusions and importance: Our findings demonstrate that CNV may occur in the course of tuberculous chorioretinitis with marked loss of vision, and management with anti-tuberculosis medications, oral corticosteroids, and intravitreal anti-VEGF injections results in notable improvement in their clinical course.